• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病中的血管功能障碍:病理过程的前奏还是其结果?

Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It?

作者信息

Govindpani Karan, McNamara Laura G, Smith Nicholas R, Vinnakota Chitra, Waldvogel Henry J, Faull Richard Lm, Kwakowsky Andrea

机构信息

Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

出版信息

J Clin Med. 2019 May 10;8(5):651. doi: 10.3390/jcm8050651.

DOI:10.3390/jcm8050651
PMID:31083442
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6571853/
Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia. Despite decades of research following several theoretical and clinical lines, all existing treatments for the disorder are purely symptomatic. AD research has traditionally been focused on neuronal and glial dysfunction. Although there is a wealth of evidence pointing to a significant vascular component in the disease, this angle has been relatively poorly explored. In this review, we consider the various aspects of vascular dysfunction in AD, which has a significant impact on brain metabolism and homeostasis and the clearance of β-amyloid and other toxic metabolites. This may potentially precede the onset of the hallmark pathophysiological and cognitive symptoms of the disease. Pathological changes in vessel haemodynamics, angiogenesis, vascular cell function, vascular coverage, blood-brain barrier permeability and immune cell migration may be related to amyloid toxicity, oxidative stress and apolipoprotein E (APOE) genotype. These vascular deficits may in turn contribute to parenchymal amyloid deposition, neurotoxicity, glial activation and metabolic dysfunction in multiple cell types. A vicious feedback cycle ensues, with progressively worsening neuronal and vascular pathology through the course of the disease. Thus, a better appreciation for the importance of vascular dysfunction in AD may open new avenues for research and therapy.

摘要

阿尔茨海默病(AD)是最常见的痴呆形式。尽管沿着几条理论和临床路线进行了数十年的研究,但针对该疾病的所有现有治疗方法都只是对症治疗。传统上,AD研究主要集中在神经元和胶质细胞功能障碍上。尽管有大量证据表明该疾病存在显著的血管成分,但这一角度的研究相对较少。在本综述中,我们考虑了AD中血管功能障碍的各个方面,其对脑代谢、内环境稳态以及β-淀粉样蛋白和其他有毒代谢产物的清除有重大影响。这可能在该疾病标志性的病理生理和认知症状出现之前就已发生。血管血流动力学、血管生成、血管细胞功能、血管覆盖、血脑屏障通透性和免疫细胞迁移的病理变化可能与淀粉样蛋白毒性、氧化应激和载脂蛋白E(APOE)基因型有关。这些血管缺陷可能反过来导致多种细胞类型的实质淀粉样蛋白沉积、神经毒性、胶质细胞活化和代谢功能障碍。随之而来的是一个恶性循环,在疾病过程中神经元和血管病理状况逐渐恶化。因此,更好地认识血管功能障碍在AD中的重要性可能为研究和治疗开辟新的途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fc/6571853/4424c7854211/jcm-08-00651-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fc/6571853/4424c7854211/jcm-08-00651-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fc/6571853/4424c7854211/jcm-08-00651-g001.jpg

相似文献

1
Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It?阿尔茨海默病中的血管功能障碍:病理过程的前奏还是其结果?
J Clin Med. 2019 May 10;8(5):651. doi: 10.3390/jcm8050651.
2
Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.阿尔茨海默病中血脑屏障功能障碍:来自人体研究的证据。
Neuropathol Appl Neurobiol. 2022 Apr;48(3):e12782. doi: 10.1111/nan.12782. Epub 2022 Feb 2.
3
Cooperation between neurovascular dysfunction and Aβ in Alzheimer's disease.阿尔茨海默病中神经血管功能障碍与β淀粉样蛋白之间的相互作用。
Front Mol Neurosci. 2023 Aug 16;16:1227493. doi: 10.3389/fnmol.2023.1227493. eCollection 2023.
4
Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.阿尔茨海默病中的神经血管机制与血脑屏障紊乱
Acta Neuropathol. 2009 Jul;118(1):103-13. doi: 10.1007/s00401-009-0522-3. Epub 2009 Mar 25.
5
Impact of apolipoprotein E isoforms on sporadic Alzheimer's disease: beyond the role of amyloid beta.载脂蛋白E亚型对散发性阿尔茨海默病的影响:超越β淀粉样蛋白的作用
Neural Regen Res. 2024 Jan;19(1):80-83. doi: 10.4103/1673-5374.375316.
6
Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease.脑灌注不足和葡萄糖低代谢:关键病理生理调节因子促进神经退行性变、认知障碍和阿尔茨海默病。
J Neurosci Res. 2017 Apr;95(4):943-972. doi: 10.1002/jnr.23777. Epub 2016 Jun 27.
7
Impact of Tau on Neurovascular Pathology in Alzheimer's Disease.Tau蛋白对阿尔茨海默病神经血管病理的影响
Front Neurol. 2021 Jan 7;11:573324. doi: 10.3389/fneur.2020.573324. eCollection 2020.
8
Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease.阿尔茨海默病神经病理生理机制中的恶性循环。
Curr Alzheimer Res. 2006 Apr;3(2):95-108. doi: 10.2174/156720506776383068.
9
Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.阿尔茨海默病与“缺失”假说:β-淀粉样蛋白对内皮细胞和神经元毒性的机制
Med Hypotheses. 2005;65(1):123-37. doi: 10.1016/j.mehy.2004.08.031.
10
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.植物环烯醚萜类化合物在阿尔茨海默病和帕金森病中的治疗潜力:综述。
Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8.

引用本文的文献

1
Polyphenols and Alzheimer's Disease: A Review on Molecular and Therapeutic Insights With In Silico Support.多酚与阿尔茨海默病:基于计算机辅助支持的分子与治疗见解综述
Food Sci Nutr. 2025 Aug 28;13(9):e70496. doi: 10.1002/fsn3.70496. eCollection 2025 Sep.
2
and as Modifiers of Age of Onset in Autosomal-Dominant Early-Onset Alzheimer's Disease Caused by the A431E Variant.以及作为由A431E变体引起的常染色体显性早发性阿尔茨海默病发病年龄的修饰因子。
Int J Mol Sci. 2025 Aug 16;26(16):7929. doi: 10.3390/ijms26167929.
3
Sex differences in clinical risk factors for Alzheimer's dementia patients with early-onset and late-onset.

本文引用的文献

1
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.血压和血脂降低对认知的影响:HOPE-3 研究结果。
Neurology. 2019 Mar 26;92(13):e1435-e1446. doi: 10.1212/WNL.0000000000007174. Epub 2019 Feb 27.
2
Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.将阿尔茨海默病中的淀粉样蛋白清除作为一种治疗策略。
Br J Pharmacol. 2019 Sep;176(18):3447-3463. doi: 10.1111/bph.14593. Epub 2019 Mar 11.
3
APOE genotypes in Lebanon: distribution and association with hypercholesterolemia and Alzheimer's disease.
早发型和晚发型阿尔茨海默病痴呆患者临床危险因素的性别差异。
Front Glob Womens Health. 2025 Aug 4;6:1601375. doi: 10.3389/fgwh.2025.1601375. eCollection 2025.
4
Human brain vascular multi-omics elucidates disease-risk associations.人类脑血管多组学揭示疾病风险关联。
Neuron. 2025 Jul 23. doi: 10.1016/j.neuron.2025.07.001.
5
Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.额颞叶痴呆、阿尔茨海默病和帕金森病中的共享及疾病特异性通路。
Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03833-1.
6
Immune cells in Alzheimer's disease: insights into pathogenesis and potential therapeutic targets.阿尔茨海默病中的免疫细胞:对发病机制和潜在治疗靶点的见解
Med Rev (2021). 2024 Dec 23;5(3):179-202. doi: 10.1515/mr-2024-0064. eCollection 2025 Jun.
7
A Narrative Review Evaluating Diet and Exercise as Complementary Medicine for the Management of Alzheimer's Disease.一项评估饮食和运动作为阿尔茨海默病管理补充医学的叙述性综述。
Nutrients. 2025 May 26;17(11):1804. doi: 10.3390/nu17111804.
8
Evaluating the Causal Association Between Type 2 Diabetes and Alzheimer's Disease: A Two-Sample Mendelian Randomization Study.评估2型糖尿病与阿尔茨海默病之间的因果关联:一项两样本孟德尔随机化研究。
Biomedicines. 2025 Apr 30;13(5):1095. doi: 10.3390/biomedicines13051095.
9
Multisystem failure, tipping points, and risk of Alzheimer's disease.多系统衰竭、临界点与阿尔茨海默病风险
Alzheimers Dement. 2025 May;21(5):e70249. doi: 10.1002/alz.70249.
10
Temporal transcriptomic changes in the THY-Tau22 mouse model of tauopathy display cell type- and sex-specific differences.tau蛋白病的THY-Tau22小鼠模型中的时间转录组变化表现出细胞类型和性别特异性差异。
Acta Neuropathol Commun. 2025 May 7;13(1):93. doi: 10.1186/s40478-025-02013-z.
黎巴嫩的载脂蛋白E基因型:分布及其与高胆固醇血症和阿尔茨海默病的关联
Per Med. 2019 Jan;16(1):15-23. doi: 10.2217/pme-2018-0067. Epub 2018 Nov 20.
4
Blood-Brain Barrier Integrity and Clearance of Amyloid-β from the BBB.血脑屏障完整性和 BBB 中淀粉样蛋白-β的清除。
Adv Exp Med Biol. 2018;1097:261-278. doi: 10.1007/978-3-319-96445-4_14.
5
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).淀粉样蛋白正电子发射断层扫描和脑脊液结果来自 crenezumab 抗淀粉样蛋白-β 抗体在轻度至中度阿尔茨海默病(BLAZE)的双盲、安慰剂对照、随机 2 期研究。
Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5.
6
Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults.他汀类药物与大脑健康:老年人的阿尔茨海默病和脑血管疾病生物标志物。
J Alzheimers Dis. 2018;65(4):1345-1352. doi: 10.3233/JAD-180446.
7
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.阿尔茨海默病预防计划常染色体显性阿尔茨海默病试验:一项在临床前E280A突变携带者中比较克瑞珠单抗与安慰剂的研究,以评估治疗常染色体显性阿尔茨海默病的疗效和安全性,其中包括一个接受安慰剂治疗的非携带者队列。
Alzheimers Dement (N Y). 2018 Mar 8;4:150-160. doi: 10.1016/j.trci.2018.02.002. eCollection 2018.
8
Microglia in Alzheimer's Disease: Activated, Dysfunctional or Degenerative.阿尔茨海默病中的小胶质细胞:激活、功能失调还是退化
Front Aging Neurosci. 2018 May 11;10:140. doi: 10.3389/fnagi.2018.00140. eCollection 2018.
9
Unique and shared inflammatory profiles of human brain endothelia and pericytes.人脑内皮细胞和周细胞的独特和共同的炎症特征。
J Neuroinflammation. 2018 May 11;15(1):138. doi: 10.1186/s12974-018-1167-8.
10
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.ABBY:卡瑞兹单抗治疗轻度至中度阿尔茨海默病的 2 期随机试验。
Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.